beckman coulter

J.P. Morgan reports Beckman Coulter (NYSE: BEC) may be on the sales block. In a note to clients, J.P. Morgan writes, "Multiple news sources, including Bloomberg, The Wall Street Journal, and The New York Times, are reporting that Beckman Coulter is actively exploring a sale, having been approached...

JP Morgan has raised the price target on Beckman Coulter (NYSE: BEC) from $62 to $74.

As sentiment remains negative on Beckman Coulter, Inc. (NYSE: BEC), J.P. Morgan said that it remains Overweight on shares of BEC. “Despite a short-covering rally following Q3 results, sentiment remains generally bearish based on our conversations with investors,” J.P. Morgan writes. “We continue to...

Morgan Joseph is changing the price target of the following companies: Bally Technologies, Inc. (NYSE: BYI) $44 to $42 Beckman Coulter, Inc. (NYSE: BEC) $56 to $62

Although Beckman Coulter, Inc. (NYSE: BEC) remains a substantial player in the central lab, “we have concerns about the macro backdrop and management's ability to blunt the impact of Troponin (TnI) missteps and prevent the fire from spreading to allied clinical segments,” Jefferies & Company...

Beckman Coulter, Inc. (NYSE: BEC) announced that Scott Garrett, the current Chairman, President, and CEO, is resigning after eight years, but will continue as a full-time, non-executive employee of the company through January 15, 2011 to assist the board through the transitional period, Jefferies...